Author:
Fan Rong,Zhong Jie,Zheng Sichang,Wang Zhengting,Xu Ying,Li Shuyi,Zhou Jie,Yuan Fei
Publisher
Springer Science and Business Media LLC
Reference43 articles.
1. Kanda T. Criminal or bystander: imatinib and second primary malignancy in GIST patients. Chin J Cancer Res. 2013;25(5):490–2.
2. Datar M, Khanna R. Inpatient burden of gastrointestinal stromal tumors in the United States. J Gastrointest Oncol. 2012;3(4):335–41.
3. Li ZY, Tang L, Li SX, Shan F, Bu ZD, Ji JF. Imatinib mesylate in clinically suspected gastric stromal tumors. Chin J Cancer Res. 2013;25(5):600–2.
4. Patel S. Exploring novel therapeutic targets in GIST: focus on the PI3K/Akt/mTOR pathway. Curr Oncol Rep. 2013;15(4):386–95.
5. Patel S. Long-term efficacy of imatinib for treatment of metastatic GIST. Cancer Chemother Pharmacol. 2013;72(2):277–86.
Cited by
36 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献